stoxline Quote Chart Rank Option Currency Glossary
Surface Oncology, Inc. (SURF)
1.07  -0.01 (-0.93%)    09-07 16:00
Open: 1.06
High: 1.09
Volume: 1,462,284
Pre. Close: 1.08
Low: 1.01
Market Cap: 65(M)
Technical analysis
2023-10-20 4:26:40 PM
Short term     
Mid term     
Targets 6-month :  1.3 1-year :  1.52
Resists First :  1.12 Second :  1.3
Pivot price 1.03
Supports First :  0.93 Second :  0.82
MAs MA(5) :  1.07 MA(20) :  1
MA(100) :  0.84 MA(250) :  0.87
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  79.7 D(3) :  81.7
RSI RSI(14): 61.4
52-week High :  1.42 Low :  0.55
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ SURF ] has closed below upper band by 31.0%. Bollinger Bands are 13.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.07 - 1.08 1.08 - 1.08
Low: 1.06 - 1.06 1.06 - 1.07
Close: 1.06 - 1.07 1.07 - 1.08
Company Description

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited to develop, manufacture, and commercialize antibodies that targets SRF813; and license agreement with Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Headline News

Wed, 13 Sep 2023
Latham Watkins Advises Coherus BioSciences in Acquisition of Surface Oncology - Latham & Watkins LLP -

Mon, 11 Sep 2023
Coherus acquires immuno-oncology company Surface - Pharmaceutical Technology

Fri, 08 Sep 2023
Coherus Completes Surface Oncology Acquisition - Yahoo Finance

Thu, 31 Aug 2023
Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote “FOR” the Proposed Merger ... - Yahoo Finance

Tue, 15 Aug 2023
Surface Oncology And Coherus BioSciences: Does A Buyout Equal A Good Deal? - Seeking Alpha

Mon, 19 Jun 2023
Coherus BioSciences to acquire Surface Oncology for $65m - Pharmaceutical Technology

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 61 (M)
Shares Float 49 (M)
Held by Insiders 7.2 (%)
Held by Institutions 46 (%)
Shares Short 165 (K)
Shares Short P.Month 285 (K)
Stock Financials
EPS -1.56
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.81
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -41.5 %
Return on Equity (ttm) -105.8 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) -0.61
Sales Per Share 0
EBITDA (p.s.) -1.37
Qtrly Earnings Growth 0 %
Operating Cash Flow -84 (M)
Levered Free Cash Flow -52 (M)
Stock Valuations
PE Ratio -0.69
PEG Ratio 0
Price to Book value 1.32
Price to Sales 0
Price to Cash Flow -0.78
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android